Membrane transporters control cerebrospinal fluid formation independently of conventional osmosis to modulate intracranial pressure

Eva K. Oernbo†, Annette B. Steffensen†, Pooya Razzaghi Khamesi2, Trine L. Toft-Bertelsen1, Dagne Barbuskaite1, Frederik Vilhardt3, Niklas J. Gerkaub, Katerina Tritsaris3, Anja H. Simonsen5, Sara D. Lolansen1, Søren N. Andreassen1, Steen G. Hasselbalch5, Thomas Zeuthen1, Christine R. Rose4, Vartan Kurtcuoglu2 and Nanna MacAulay1*

Abstract

Background: Disturbances in the brain fluid balance can lead to life-threatening elevation in the intracranial pressure (ICP), which represents a vast clinical challenge. Nevertheless, the details underlying the molecular mechanisms governing cerebrospinal fluid (CSF) secretion are largely unresolved, thus preventing targeted and efficient pharmaceutical therapy of cerebral pathologies involving elevated ICP.

Methods: Experimental rats were employed for in vivo determinations of CSF secretion rates, ICP, blood pressure and ex vivo excised choroid plexus for morphological analysis and quantification of expression and activity of various transport proteins. CSF and blood extractions from rats, pigs, and humans were employed for osmolality determinations and a mathematical model employed to determine a contribution from potential local gradients at the surface of choroid plexus.

Results: We demonstrate that CSF secretion can occur independently of conventional osmosis and that local osmotic gradients do not suffice to support CSF secretion. Instead, the CSF secretion across the luminal membrane of choroid plexus relies approximately equally on the Na⁺/K⁺/2Cl⁻ cotransporter NKCC1, the Na⁺/HCO₃⁻ cotransporter NBCe2, and the Na⁺/K⁺-ATPase, but not on the Na⁺/H⁺ exchanger NHE1. We demonstrate that pharmacological modulation of CSF secretion directly affects the ICP.

Conclusions: CSF secretion appears to not rely on conventional osmosis, but rather occur by a concerted effort of different choroidal transporters, possibly via a molecular mode of water transport inherent in the proteins themselves. Therapeutic modulation of the rate of CSF secretion may be employed as a strategy to modulate ICP. These insights identify new promising therapeutic targets against brain pathologies associated with elevated ICP.

Keywords: Cerebrospinal fluid, Choroid plexus, Osmosis, Cotransport, Intracranial pressure

Introduction

Our brain contains 80% water as the major constituent of the cerebrospinal fluid (CSF) that surrounds the brain tissue and fills the ventricles, the interstitial and intracellular fluid, and the blood contained in the cerebral...
vasculature. The CSF protects the brain from mechanical insults and serves as a route for dispersion of hormones, nutrients, and metabolites between brain structures and neighboring cells. The CSF is replenished at a rate of approximately 500 ml/day in the adult human [1], the majority of which is secreted across the choroid plexus epithelium residing in the ventricles [2, 3]. The CSF disperses in the brain prior to entering the proposed exit routes along the lymphatic and/or perineural pathways [4–7]. CSF dynamics are finely tuned to ensure stable brain water content and an intracranial pressure (ICP) within the physiological range [8]. However, many brain pathologies are associated with CSF accumulation, e.g., in the form of hydrocephalus or brain edema. An elevation in ICP may be debilitating or even fatal to the patient if left untreated. The prevalent mode of ICP management under these conditions relies on surgical intervention such as ventricular shunt implantation or craniectomy, which are highly invasive and associated with severe side effects and/or need for recurring revisions [9, 10]. Pharmacological approaches towards ICP reduction generally fail due to questionable efficiency and/or intolerable side effects [11–13]. This failure relates to our incomplete understanding of the molecular mechanisms underlying the CSF secretion and therefore the lack of rational targets for directed and specific therapy. It is generally assumed that CSF secretion takes place by conventional osmotic water transport, where water follows the osmotic gradient that results from electrolyte transport across the choroid plexus epithelium [14]. For such manner of osmotic water flux to sustain the entire CSF secretion, however, an adequate osmotic gradient and a sufficient water permeability must exist across the choroidal epithelium. Alternatively, local osmotic gradients could potentially generate favorable conditions for fluid flow across the choroid plexus epithelium. Neither of these have been demonstrated experimentally, rendering the molecular mechanism of CSF secretion unresolved [3]. The Na⁺/K⁺/2Cl⁻ cotransporter 1 (NKCC1) was recently proposed as a key contributor to CSF secretion in mice [15] and rats [16], and may do so via its ability to promote fluid transport [17, 18]. This manner of water transport appears to occur by a mechanism within the protein itself [19, 20] and therefore does not require a bulk trans-epithelial osmotic gradient [21]. Other transporters expressed in the choroid plexus epithelial cells may share this feature. In this study, we aimed to resolve the pivotal question of how CSF is secreted across the choroid plexus, and demonstrate that CSF secretion can occur independently of a bulk trans-epithelial osmotic gradient. The CSF secretion across the luminal membrane does not depend on local osmotic gradients, but is supported by a concerted effort of cotransporters and pumps present in the choroidal epithelium, possibly via transport of water by a mechanism inherent in the transport proteins. Such mode of fluid transport eliminates the necessity for large osmotic gradients between the vasculature and the brain. Importantly, the definition of such specific molecular targets will allow pharmacological interference with the CSF secretion to reduce ICP in disease.

**Methods**

**Patient samples**

Fourteen elderly and evenly sex-distributed individuals (mean age: 67 y, range: 58–81 y, 9 F/11 M) were included in the study. Lumbar CSF samples and corresponding serum samples were obtained from the Danish Dementia Biobank at the Danish Dementia Research Centre (Copenhagen University Hospital, Rigshospitalet, DK) together with relevant clinical information. Patients gave consent for using samples for research purposes according to the guidelines given by the Ethics committee of the Capital Region of Denmark. All elderly control individuals were screened, but cleared, for dementia, mild cognitive impairment, and normal pressure hydrocephalus [22–24]. To evaluate the impact of different blood sampling methods on the osmolality (in mosmol per kg, termed mOsm henceforward), blood samples from seven healthy volunteers were included (mean age: 32 years, range: 23–39 years, 5 F/2 M).

**Animals**

All animal experiments conformed to the legislations for animal protection and care in the European Community Council Directive (2010/63/EU) and followed all ethical regulations under the animal permission no. 2016-15-0201-00944 and 2018-15-0201-01595 authorized by the Danish Animal Inspectorate or the institutional act no. O50/05 approved by the Animal Welfare Office at the Animal Care and Use Facility of the Heinrich Heine University Düsseldorf. Adult male Sprague Dawley rats (Janvier Labs) at 9 ± 1 weeks of age were used for physiological experimentation. The animals were housed with a 12:12 light cycle and had free access to water and food. Animals were randomly allocated to each treatment group, and all experimental work was performed and reported in compliance with the ARRIVE guidelines [25]. The sample size for all animal experiments was determined with power calculations [15]. Additional biosamples (choroid plexus, CSF, blood) were obtained from adult female Danish landrace pigs (weight ~ 60 kg, conventional producer with blue SPF status) under the animal permission 2016-15-0201-00845.
Anesthesia
Rats were anesthetized with an intraperitoneal (i.p.) injection of xylazine and ketamine (6 mg ml⁻¹ and 60 mg ml⁻¹ in sterile water, 0.17 ml per 100 g body weight, ScanVet). To sustain anesthesia, rats were re-dosed with a half ketamine dose upon detection of foot reflexes after pinching (approximately every 20-40 min). When indicated, isoflurane (Attane vet, 1000 mg/g isoflurane, ScanVet) was employed using 4–5% (mixed with 0.9 l min⁻¹ humified air with 0.1 l min⁻¹ O₂ for terminal procedures or 1.8 l min⁻¹ air/0.1 l min⁻¹ O₂ for survival procedures) to induce anesthesia in an induction chamber and 2–2.5% to maintain anesthesia through a face mask, which was gradually decreased to 1% during the surgery.

Solutions and chemicals
The majority of the experiments were conducted in CO₂/HCO₃⁻-buffered artificial cerebrospinal fluid (HCO₃⁻-aCSF; (in mM) 120 NaCl, 2.5 KCl, 2.5 CaCl₂, 1.3 MgSO₄, 1 NaH₂PO₄, 10 glucose, 25 NaHCO₃, buffered with 95% O₂/5% CO₂ to obtain a pH of 7.4). In experiments where the solution could not be equilibrated with 95% O₂/5% CO₂, it was instead buffered by HEPES (HEPES-aCSF; (in mM) 120 NaCl, 2.5 KCl, 2.5 CaCl₂, 1.3 MgSO₄, 1 NaH₂PO₄, 10 glucose, 17 Na-HEPES, adjusted to pH 7.4 with NaOH). All pharmacological inhibitors were purchased from Sigma. Pharmacological inhibitors were dissolved in DMSO and kept as stock solutions at −20 °C (bumetanide: B3023, cariporide: SML1360, S0859: SML0638) or dissolved directly into the solution (furosemide: F4381, ouabain: O3125, DIDS: D3514) on the day of experiment. All solutions included the appropriate vehicle; mostly addition of 0.05% DMSO (D8418, Sigma). The fluorescent dyes calcein-AM (C1359, Sigma or IRDye 800 CW, P/N 929-08972, LI-COR) and the hemoglobin (Hb) content were determined using an ABL80 (Radiometer, Additional file 1: Fig. S1f–i).

Ventriculo-cisternal perfusion
Anesthetized and ventilated rats were placed in a stereotaxic frame (Harvard Apparatus) in a prone position. Anaesthetized and ventilated rats were placed in a stereotaxic frame (Harvard Apparatus) in a prone position. A dorsal midline incision was made over the skull and upper cervical spine to expose the cranium, after which a burr hole was drilled (0.5 mm drill bit) using the coordinates: 1.3 mm posterior to bregma, 1.8 mm lateral to the midline, and ~0.6 mm ventral through the skull. A brain infusion cannula (Brain infusion kit2 with 1 mm adjustment spacers, Alzet) was placed into the lateral ventricle via the burr hole and glued to the skull (Superglue, Pelikan). The perfusion solution (HCO₃⁻-aCSF containing 1 mg ml⁻¹ TRITC-dextran and 0.05–0.10% DMSO vehicle) was pH calibrated and heated to 37 °C by an inline heater (SF-28, Warner Instruments) prior to entering the infusion cannula. After securing access through the neck muscle layer, a glass capillary (300-0067, Harvard Apparatus pulled by a Brown Micropipette puller, Model P-97, Sutter Instruments) was introduced at a 5° angle into cisterna magna (~7.5 mm distal to the occipital bone and ~1.5 mm lateral to the muscle-midline). The HCO₃⁻-aCSF was continuously infused into the lateral ventricle at a rate of 9 µl min⁻¹ using a peristaltic pump.
CSF was collected from cisterna magna in 5 min intervals from a second glass capillary (30-0065, Harvard Apparatus) placed into the first capillary. The cisterna magna puncture and continuous fluid sampling prevents elevation of the ICP during the procedure. For experiments including pharmacological inhibitors, the solution was changed after 1 h infusion to a HCO$_3^-$-aCSF containing the transport inhibitor (100 µM bumetanide, 5 mM ouabain, 1.5 mM DIDS, or 50 µM cariporide, all expected to be diluted at least ~ 1:1 upon ventricular entrance, due to the comparable rates of aCSF delivery and CSF secretion). These inhibitor concentrations were chosen because (i) a lower concentration of the drug is expected to enter the contralateral ventricle, (ii) the introduced inhibitors not expected to reach the choroid plexuses at full concentration with continuous bulk flow of the CSF in addition to the ‘wash-away’ of the inhibitors from the choroid plexus surface by the continuous CSF secretion [26]. The fluorescence in the collected sample fluids was measured using the Synergy™ Neo2 Multi-mode Microplate Reader (BioTek Instruments). The CSF production rate was calculated from the equation:

$$V_p = ri * (Ci - Co)$$

where $V_p$ = CSF production rate ($\mu$l min$^{-1}$), $r_i$ = infusion rate ($\mu$l min$^{-1}$), $C_i$ = fluorescence of inflow solution, $C_o$ = fluorescence of outflow solution, calculated 50–65 min after infusion initiation (baseline) and 100–120 min after infusion initiation (inhibitor effect). Different ventricular osmolalities were obtained by unilateral infusion of a hyper- or hyposmolar HCO$_3^-$-aCSF. Here, the control aCSF solution (307 mOsm) contained 100 mM NaCl, which was replaced with equiosmolar mannitol (105 mM). In this manner, a hyposmolar solution could be obtained by removal of mannitol (and the hyperosmolar solution with addition of mannitol). Thereby, only the osmolality, and not the electrolyte content, was altered during the experimental procedure. In one experimental series, the aCSF osmolality was adjusted with NaCl (55 mM) instead of mannitol to mimic a physiological solution. Since it is not technically possible to determine the CSF osmolality at the surface of the choroid plexus in situ, we estimate that with a combination of the continued CSF production and the pump infusion rate, the existing CSF will be diluted 1:1 with the infused aCSF. The unilateral infusion of aCSF of a different osmolality was initiated after cisterna magna puncturing and continued for 75 min before termination. The CSF production rate was calculated 50–75 min after infusion initiation. In a subset of experiments, blood pressure measurements from the femoral artery were obtained. All experiments were randomized, and data analyses performed under blinded conditions.

**Live imaging of CSF tracer**

Anesthetized rats were placed in a stereotaxic frame and a burr hole drilled at coordinates 1.3 mm posterior to bregma and 1.8 mm lateral to the midline. Ventricular injections were performed with a Hamilton syringe (RN 0.40, G27, a20, Agnutho’s) inserted 4 mm into the right ventricle. 15 µl HCO$_3^-$-aCSF containing vehicle (0.1% DMSO) or each transport inhibitor (200 µM bumetanide, 2 mM ouabain, 100 µM cariporide or 300 µM S0859) was injected over 10 s. These inhibitors are expected to be swiftly diluted (approximately 10-fold) in the native ~ 150 µl CSF in both the ipsi- and contralateral ventricle, which leads to estimated functional ventricular concentrations of 20 µM bumetanide, 200 µM ouabain, 30 µM S0859 or 10 µM cariporide. HCO$_3^-$-aCSF containing carboxyate dye (10 µM) including the tested inhibitor was injected 5 min later. The rat was swiftly transferred to the Pearl Trilogy Small Animal Imaging System (LI-COR) and the head fastened in a custom-made tooth-holder that enabled stable head position during imaging. Exactly 1 min after the second injection, imaging was initiated with 30 s intervals for 5 min (800 nm channel, 85 µm resolution). A white image was obtained at the termination of each experiment. To verify bilateral reach of inhibitor and carboxylate, the ventricles of separated hemispheres from the isolated rat brain were imaged subsequently. The fluorescence signals were analyzed in Image Studio 5.2 with the ROIs defined from the white image as a square starting at lambda. Quantification of the relative 2D movement of dye over time is shown as fluorescent signals at given time points normalized to the first image fluorescent signal. Quantifications were performed in a blinded manner.

**ICP monitoring**

Anesthetized and ventilated rats, kept at 37 °C body temperature, were placed into a stereotaxic frame. The skull was exposed through a dorsal midline incision, a burr hole drilled, and a 4 mm brain infusion cannula was placed into the lateral ventricle (coordinates of 1.3 mm posterior to bregma, 1.8 mm lateral to the midline, and ~0.6 mm ventral through the skull). A cranial window (~ 4 mm diameter) was drilled on the contralateral side of the skull with care taken not to damage the dura. An epidural probe (PlasticsOne, C313G, with the ICP cannula cut to be level with the base of the pedestal) was lowered into the hole, and secured with dental resin cement (Panavia SA Cement, Kuraray Noritake Dental Inc.). The ICP cannula was pre-filled with HEPES-aCSF and connected to a pressure transducer (APT300)
and transducer amplifier module TAM-A (both from Hugo Sachs Elektronik). The pressure signal was visualized and recorded with a 1 kHz sampling rate using BDAS Basic Data Acquisition Software (Harvard Apparatus, Hugo Sachs Elektronik). To assure a continuous fluid column between the dura and the epidural probe, approximately 5 µl of HEPES-aCSF was injected through the epidural probe, after which the ICP signal stabilized within 15 min. Ventricular infusion of heated and pH-equilibrated HCO₃⁻-aCSF with vehicle (0.9% DMSO) was initiated with 0.5 µl min⁻¹ by a peristaltic pump (or 1.5 µl min⁻¹ for a selected set of experiments) for 45 min with subsequent solution switch to an HCO₃⁻-aCSF containing 1.8 mM bumetanide (expected dilution to an approximate ventricular concentration of 50 µM, based on the ventricular CSF volume and the slow infusion rate of the inhibitor) and continued for 100 min. Jugular compression was applied at the initiation and termination of the experiment to confirm proper ICP recording.

Telemetric pressure monitoring
Telemetric ICP monitoring was performed using KAHA Sciences rat dual pressure telemetric system. Animals were anaesthetized by isoflurane inhalation, the body temperature was maintained at 37 °C, and the surgical areas sterilized using 0.5% chlorhexidine (Medic). Analgesia was injected s.c. prior and post-surgery (48 h) and contained 5 mg kg⁻¹ Caprofen (Norodyl Vet, Norbrook), 0.05 mg kg⁻¹ buprenorphine (Tamegic, Indivior), and 200 mg + 40 mg kg⁻¹ sulfadiazin and trimethoprim (Borgal Vet). The implantation procedure was performed under aseptic conditions as described in [27]. Briefly, the blood flow of the abdominal aorta was occluded (4–0 silk suture threads, Vömel) and the tip of the pressure probe inserted into the aorta using a bent 23G needle. The hole was sealed with tissue adhesive (Histoacryl, Kruuse or 454285, Greiner-Bio One), EDTA coated tubes (41.1395.105, Hounisen or 456043, Greiner Bio-One) and blood samples obtained by femoral puncture and collected in polypropylene tubes (62.610.018, Hounisen) while venous blood was collected directly from the heart or ear of the pigs. In humans, CSF samples were obtained by lumbar puncture and collected in polypropylene tubes (62.610.018, Hounisen) and blood samples obtained by venepuncture. Several blood collection tubes were used for blood analysis; heparin coated tubes (290353 Kruuse or 454285, Greiner-Bio One), EDTA coated tubes (41.1395.105, Hounisen or 456043, Greiner Bio-One) and serum tubes (454067, Geiner-Bio One). Immediately after collection, blood and CSF samples were centrifuged at 2000g for 10 min at 4 °C (blood collected in serum tubes was allowed to clot for 30 min at room temperature before centrifugation). Pellets were discarded and supernatant of human samples stored in −80 °C pending analysis, while the animal samples were analyzed freshly. Prior to osmolality measurements, animal samples were kept on 4 °C (up to max 1 h), while frozen human samples were thawed and kept on ice (max 4 h). 100 µl supernatant was transferred to osmometer tubes (72.690.001, VWR) and the osmolality was determined in duplicate samples using a freezing point depression osmometer (Löser, Type 15) with a ± 1 mOsm accuracy.

Electron microscopy
Acutely isolated choroid plexus was fixed immediately in 2% glutaraldehyde in phosphate buffer, pH 7.2, before standard processing for either conventional transmission electron microscopy (TEM) or for scanning electron microscopy (SEM). 50 nm TEM sections were examined in a CM 100 microscope and images acquired with an Olympus Veleta camera at a resolution of 2048 × 2048. Scanning EM samples were observed in a FEI Quanta...
3D FEG dual beam scanning microscope and images acquired at a resolution of 2048 × 2048. Microvillus length was estimated by the track length function of ImageJ using scanning EM images (to unequivocally follow the same microvillus; n = 10 cells, 45 microvilli). The microvillus diameter was determined in TEM cross sections, and the linear density of microvilli was estimated by counting microvilli continuous with the cell surface per μm of bulk membrane (ImageJ); to obtain microvillar density, the result was integrated over 1 μm².

Mathematical modelling of CSF secretion

A mathematical model of osmotic water transfer into the inter-microvillar space of the choroid plexus luminal membrane was developed based on data from above-described physiological experiments and transmission electron microscopy (see Additional file 2). The functional unit of the model is the volume between four microvilli, simplified as a hydraulically equivalent circular cylindrical space. Solutes are continuously supplied into this space through the adjacent membrane segments, producing an osmotic gradient that draws intracellular water. Assuming steady state conditions, the local solute flux corresponds to the rate of solute removal by bulk CSF drainage divided by the total lateral and base surface areas of all functional units. Fluid velocity and solute concentration distribution along the longitudinal axis of a functional unit were determined through a set of coupled steady-state differential equations originally proposed by Diamond and Bossert [29], see Additional file 2. The model equations were solved in MATLAB Release bvp4c. The implementation was validated against published results [29]. Computational mesh independence was tested for and confirmed.

Volume recordings

Acutely isolated rat choroid plexus was mounted on coverslips coated with Cell-Tak® (Corning) and placed in a POCmini2 open perfusion chamber (PeCon) mounted in a 37 °C heating chamber of an inverted confocal microscope (Carl Zeiss, Cell-Observer with a Yokogawa X1 spinning disk, 10 × 0.3 NA EC Plan Neofluar objective). The choroid plexus was loaded with calcein-AM (17 μM, 10 min) prior to washout of excess fluorophore with ~ 1 ml min⁻¹ continuous HEPES-aCSF flow induced by gravity. Imaging was initiated (488 nm, 50 ms exposure) and the emitted fluorescence recorded at an acquisition rate of 1 Hz (Hamamatsu Orca Fusion) with the ZEN software. An additional 100 ± 1 mOsM was added to the HEPES-aCSF by inclusion of either 100 mM mannitol, 55 mM NaCl or 55 mM KCl. All experiments were randomized prior to execution and the subsequent analysis carried out in an experimenter-blinded fashion. Images were converted to black/white (background/choroid plexus) using Gaussian blur threshold in ImageJ (NIH). To obtain the response of a tissue as a whole, the response was recorded as the average of the five regions of interest placed with 50% choroid plexus and 50% background. The two-dimensional distribution change was employed as a proxy for choroid plexus volume changes and was determined as a function of time.

Imaging of Na⁺ and pH

Acutely isolated lateral choroid plexus kept in HCO₃⁻-aCSF was bolus-loaded with the Na⁺-sensitive fluorescent probe SBFI-AM (150 μM) or with the pH-sensitive fluorescent probe BCECF-AM (125 μM) by pressure-application onto several regions of the isolated tissue following a procedure introduced by Stosiek et al. [30]. To this end, the dye stocks were diluted, resulting in a final concentration of 150 μM and 125 μM (SBFI-AM and BCECF-AM, respectively; final concentration of Pluronic: 2.5–3%). Dyes were injected into the tissue for a duration of about 1 s using a fine glass pipette (1 μm tip diameter) and with ongoing bath perfusion. After dye loading, the tissue was washed by HCO₃⁻-aCSF perfusion for a minimum of ~ 45 min to allow for de-esterification of the dye. For wide-field Na⁺ and pH imaging, a variable scan digital imaging system (Nikon NIS-Elements v4.3, Nikon GmbH) in connection with an upright microscope (Nikon Eclipse FN-PT, Nikon GmbH) was employed. It hosted a 40 x water immersion objective (Nikon Fluor 40 x/0.8 N.A., Tokyo, Japan) coupled to a Poly-V monochromator (Thermo Scientific/FEI, Planegg, Germany) and an ORCA Flash 4.0LT camera (Hamamatsu Photonics, Herrsching, Germany) for collecting fluorescence emission. SBFI was excited at 340 and 380 nm and emission collected > 440 nm with a sampling rate of 0.5 Hz. BCECF was excited at 452 and 488 nm and emission collected between 490 and 575 nm (sampling rate of 0.2 Hz). Each choroid plexus was imaged for 2 min in HCO₃⁻-aCSF to record the baseline. In Na⁺ imaging experiments, this was followed by wash-in of HCO₃⁻-aCSF containing transporter inhibitors and imaging for five min in the presence of these (20 μM bumetanide [31], 2 mM ouabain [32], 30 μM S0859, or 10 μM cariporide [33], or corresponding DMSO vehicle). In pH imaging experiments, 5 mM NH₄Cl was washed in for 10 min and imaging continued for another 18 min either in the absence or in the presence of the NHE1 inhibitor cariporide (10 μM). Analysis of fluorescence derived from SBFI or BCECF was performed from a region of interest (ROI) and background-correction carried out for each ROI and each wavelength. Afterwards, the fluorescence ratio was calculated (F₃40/F₃80) for SBFI.
and $F_{68}/F_{48}$ for BCECF) using the OriginPro Software (OriginLab Corporation v.9.0). The NKCC1 inhibitor bumetanide shows autofluorescence when excited at 340 nm, the “sodium-insensitive” wavelength of SBFI. Bath application of bumetanide thus resulted in a rapid, stepwise increase in fluorescence upon excitation at 340 nm in all investigated ROIs, including those chosen for background correction. Washout of bumetanide resulted in a likewise rapid decrease in fluorescence at 340 nm. Comparable fast changes in fluorescence emission following wash-in or wash-out of bumetanide were not observed upon excitation at 380 nm (“sodium-sensitive wavelength”), indicating negligible autofluorescence of bumetanide at this wavelength. In the following, autofluorescence was thus corrected as reported before for cultured astrocytes exposed to furosemide [34] or for choroid plexus exposed to bumetanide [20]. To this end, the fluorescence recorded from a ROI in the field of view apparently free of SBFI-loaded cellular structures (“background”) was subtracted from each individual ROI containing cellular structures, resulting in extinction of the fast autofluorescence-induced signal (see also [34]). To determine changes in $Na^+$ flux rates, linear regression analyses were performed on the rate of fluorescence change upon inhibitor infusion. Data analyses were carried out in a blinded fashion.

**$^{86}$Rb$^+$ efflux**

Acutely isolated choroid plexus from anesthetized rats and pigs was allowed to recover in $37 ^\circ C$ HCO$_3^-$-aCSF for 5–10 min (pig choroid plexus was dissected into smaller pieces) prior to exposure to the two isotopes in $37 ^\circ C$ HCO$_3^-$-aCSF for 10 min; $^{86}$Rb$^+$ (1 $\mu$Ci ml$^{-1}$, NEZ07200, Perkin Elmer) and $^3$H-mannitol (4 $\mu$Ci ml$^{-1}$, NET101, Perkin Elmer), the latter serves as an extracellular marker [35]. The choroid plexus was briefly (15 s) washed in aCSF containing vehicle, bumetanide (20 $\mu$M), or furosemide (1 mM). 0.2 ml of the surrounding aCSF was collected (and replaced) every 20 s and placed in scintillation vials. At the termination of the experiment, the choroid plexus was dissolved overnight at room temperature in 1 ml Solvable (6NE9100, Perkin Elmer) and combined with the remaining efflux solution. Determination of isotope content was obtained in Ultima Gold™ XR scintillation liquid (6013119, Perkin Elmer) with a Tri-Carb 2900TR Liquid Scintillation Analyzer (Packard). For each time point, the $^{86}$Rb$^+$ level was corrected for $^3$H-mannitol (extracellular background). Data are shown as the natural logarithm of the $^{86}$Rb$^+$ level at time point, $T$, ($A_T$) normalized to that of time point, 0, ($A_0$) as a function of time. The $^{86}$Rb$^+$ efflux rate constant (min$^{-1}$) was given by the slope from linear regression analysis [15, 35].

**Immunohistochemistry**

Anesthetized rats were perfusion fixed in 4% paraformaldehyde. Dissected ventricular regions (P21) or whole rat brains (9-week-old) were immersed in the fixative at 4 °C overnight. Whole brains were cryoprotected in 25% sucrose and frozen in crushed solid CO$_2$ and hippocampal brain regions were embedded in paraffin blocks. Cryostat sections (12–16 μm) were prepared and mounted on glass slides. To prepare the paraffin embedded regions, the glass slides were heated at 50–60 °C for 10 min to melt the paraffin. The heating was followed by boiling to retrieve antigens and expose the highest number of antigenic epitopes. Slides were immersed 2 × 5 min in xylene (534056, Sigma) and hydrated for 5 min in 99% ethanol (100983, Merck), 5 min in 95% ethanol, 5 min in 70% ethanol, and 5 min in deionized water prior to incubation with citrate buffer (1.6 mM citric acid (251,275, Sigma), 8.4 mM sodium citrate (1613859, Sigma) and boiled for 15 min. Cryostat sections were washed repeatedly in PBS and/or PBS-T (PBS with 0.03–0.25% Triton X-100) for 5 min and blocked in 1–10% serum diluted in PBS-T (blocking buffer) for 1–2 h at room temperature. This was followed by incubation for 30 min at room temperature and/or incubation overnight at 4 °C with primary antibodies (Rabbit anti-NKCC1: 59791, Abcam, 1:400 in blocking buffer; mouse anti-NKA α1: a6f AB 528092, DSHB, 1:300 in 1% serum in PBS-T). Sections were repeatedly washed for 5–10 min in PBS or PBS-T followed by incubation for 1–2 h with secondary antibodies (488-conjugated anti-mouse: 1:300 in serum-based (1%) PBS-T or anti-rabbit: A-11034, LifeTech, 1:500 in blocking buffer). Negative controls with secondary antibodies were run in parallel. Subsequently, sections were washed by repeated 5 min intervals in PBS-T and/or PBS. Nuclei staining with Hoechst (1:10.000 in PBS) applied between initial washes or with ProLong Gold DAPI mounting medium (Dako). Micrographs were recorded using a Zeiss LSM710 point laser (Argon Lasos RMC781272) scanning confocal microscope with a Zeiss Plan-Apochromat 63×/numerical aperture (NA) 1.4 oil objective (Carl Zeiss, Oberkochen). All micrographs were sampled in a frame scan mode.

**Western blotting**

Choroid plexus (lateral or 4th) was isolated in HEPES-aCSF, lysed in RIPA buffer (in mM: 150 NaCl, 50 Tris pH 8.0, 5 EDTA and 0.5% sodium deoxycholate, 0.1% SDS and 1% Triton X-100) with 0.4 mM pefabloc and 8 μM leupeptin, and sonicated (twice; 70% power for 30 s, Sonopuls, Bandelin) prior to protein concentration determination with the DC Protein Assay (Bio-Rad) according to the manufacturer’s instruction. 10–20 μg of total protein was loaded on precast SDS-PAGE gels (4–20%
Criterion TGX, Bio-rad) and immobilon-FL membranes (Merck Milipore) employed for the transfer. Primary and secondary antibodies were diluted 1:1 in Odyssey blocking buffer (LI-COR): PBS-T. Primary antibodies: anti-GAPDH; AB2302 (Millipore, 1:5000), anti-NKCC1; S022D (MRC PPU Reagents, 2 μg ml⁻¹), anti-KCC1 [36] (kind gift from Professor Thomas J. Jentsch, Max Delbrück Center For Molecular Medicine, Berlin, Germany, 1:500), anti-KCC2; 07–432 (Millipore, 1:1000), anti-KCC4 [37] (kind gift from Professor Jinwei Zhang, University of Dundee, UK, 2 μg ml⁻¹), anti-NKA α 1; a6F AB528092 (DSHB, 1:60), anti-NKA α 2; 07–674 (Millipore, 1:500), anti-NKA α 3; XVIF9-G10 (Thermo Fisher, 1:1000), anti-NHE1; sc-136239 (Santa Cruz, 1:500). Secondary antibodies, all 1:10,000; IRDye 680RD donkey anti-chicken (LI-COR, P/N 925-68075), IRDye 800CW/goat anti-rabbit (LI-COR, P/N 926-32211), IRDye 800CW goat anti-mouse (LI-COR, P/N 926-32210), rabbit anti-sheep (Thermofisher, SA5-10060). Images were obtained by the Odyssey CLx imaging system and analyzed by Image Studio 5.2.5 (LI-COR).

**mRNA quantification**

Total RNA was purified from rat choroid plexus embedded in RNAlater (R0901, Sigma) using the RNeasy micro kit and RNAase-free DNase set (both from Qiagen) according to manufacturer’s instructions. Reverse transcription was performed with 0.5 μg total RNA or 1 μg cRNA using the Omniscript RT mini kit (Qiagen). cDNA amplication was carried out with Light-Cycler 480 SYBR Green I Master mix (Roche) on the Stratagene Mx3005P QPCR system (Agilent Technologies). Quantitative PCR settings: initial melting at 95 °C for 10 min, 40 amplification cycles at 95 °C for 10 s, primer annealing at 60 °C for 22 s, and elongation at 72 °C for 20 s. Amplification specificity was determined from melting curves and gel electrophoresis, see primer sequence in Additional file 1: Fig. S2. Primers were designed using NCBI’s pick primer software. The optimum concentration for each primer set was determined to 200 nM except for KCC4 (300 nM). Standard curves of 4 x serial dilutions of plasmid cDNA or cDNA from reverse transcription of total RNA from either rat choroid plexus or rat total brain tissue were made in order to determine the amplification efficiencies for each of the utilized primer-sets, which were all between 90 and 110%. Data analyses were performed in GenEx (MultIDAlyses AB). The genes of interest were normalized to the two reference genes ACTB and RPS18.

**RNA sequencing**

Rat choroid plexus (lateral and 4th) was isolated in HEPES-aCSF and stored in RNAlater (R0901, Sigma) at −80 °C. The RNA extraction and library preparation were performed by Novogene Company Limited with NEB Next Ultra™ RNA Library Prep Kit (NEB) prior to RNA sequencing (paired-end 150 bp, with 12 Gb output) on an Illumina NovaSeq 6000 (Illumina). The 150 base paired-end reads were mapped to Reference genome Rnor_6.0 (Rattus norvegicus) using Spliced Transcripts Alignment to a Reference (STAR) RNA-seq aligner (v 2.7.2a) [38]. The mapped alignment generated by STAR was normalized to transcripts per million (TPM) with RSEM (version 1.3.3) [39, 40]. Gene information was gathered with mygene (v 3.1.0) python library [41, 42] (http://mygene.info), from which gene symbol, alias, and GO terms [43–45] were extracted. The list of genes annotated as ‘transporters’ was obtained from the Guide to Pharmacology webpage (target and family list) [46] and employed to generate the list of membrane transport proteins. To exclude transport proteins in intracellular membranes, the generated list was filtered by initially removing the SLC25 mitochondrial solute carrier family, ATP5 family of mitochondrial membrane ATP synthase, and the ATP6V family of vacuolar H⁺-ATPase. Subsequently, all genes were included if no GO term were present or with associated GO terms; “integral component of plasma membrane” or “plasma membrane”, but only included genes annotated as “integral component of membrane”, “membrane” or “transmembrane”, which was not also annotated as “lysosome”, “endosome membrane”, “lysosomal”, “mitochondrion”, “mitochondrial”, “golgi apparatus”, “vacuolar”, or “endoplasmic”. STAR-RNA parameter settings for library build and mapping, together with all scripts for the gene annotation and analysis can be found at https://github.com/Sorennrorge/MacAulayLab-RNAseq1.

**Xenopus laevis oocyte current recordings**

cDNA encoding rat NBCe2 was purchased from GenScript and subcloned into the oocyte expression vector pXOOM. The construct was linearized downstream from the poly-A segment, and in vitro transcribed using T7 mMessage machine according to manufacturer’s instructions (Ambion). mRNA was extracted with MEGAclear (Ambion) and microinjected into defolliculated Xenopus laevis oocytes: 50 ng NBCe2 RNA/oocyte. Xenopus laevis oocytes were purchased from EcoCyte Bioscience and kept in Kulori medium (in mM): 90 NaCl, 1 KCl, 1 CaCl₂, 1 MgCl₂, 5 HEPES (pH 7.4) for 3–4 days at 19 °C prior to experiments. Oocyte two-electrode voltage clamp was performed at room temperature using the pCLAMP 10.4 software (Molecular Devices) together with the Clamator One amplifier (model CA-1B, Dagan Co.) and the A/D converter Digidata 1440A (Molecular Devices). Borosilicate glass capillary electrodes were pulled using a vertical pipette puller (PIP 5, Heka Elektronik) to a resistance of 1MΩ.
1–3 MΩ when filled with 1 M KCl. Oocytes were subjected to a voltage clamp protocol, which comprised 200 ms steps from −120 mV to +40 mV in 20 mV increments from a holding potential of −60 mV. Currents were low-pass filtered at 500 Hz and sampled at 2 kHz. The bicarbonate-containing solution perfusing the oocyte chamber contained (in mM): NaCl 58.5; KCl 2.5; CaCl2 1; MgCl2 1; Na2HPO4 1; NaHCO3 24, HEPES 5 (pH 7.4), equilibrated with 5% CO2. The IC50 curve was made by perfusing the oocyte chamber with increasing concentrations of DIDS or S0859. Each concentration perfused the oocyte chamber for 4 min before the voltage clamp protocol was applied. Data analysis was performed in GraphPad Prism. Data were generated using at least two different oocyte batches. The current–voltage curves were obtained from the averaged currents at 160–200 ms of the voltage protocol and the IC50 curves obtained at +40 mV. The equation \( Y = Y_{\text{max}}^+ + (Y_{\text{max}}^- - Y_{\text{min}})/1 + (\text{IC50}/X)^{\text{HillSlope}} \) was used to fit the IC50 curve.

Calculations of osmotic gradients
The osmotic gradient required to support the spontaneous transport of water across the choroidal epithelium (\( \Delta \text{Osm}_{\text{req}} \) in Osm) can be calculated theoretically based on the functional water permeability across choroid plexus (LP, in cm s\(^{-1}\) Osm\(^{-1}\)), the choroidal cross-sectional area (A, in cm\(^2\)), and the CSF production rate (VP, in cm\(^3\) s\(^{-1}\)):

\[
\Delta \text{Osm}_{\text{req}} = \frac{V_P / A}{L_P}
\]

Statistics
All data are shown as mean ± SEM. To test for statistically significant differences, we performed paired or unpaired two-tailed t tests, one or two-way ANOVAs followed by Dunnett’s or Tukey’s multiple comparisons post hoc test, as indicated in figure legends. P < 0.05 was considered statistically significant. All statistical analyses were carried out with GraphPad Prism (GraphPad Software).

Results
Choroid plexus water permeability
To quantify the CSF secretion as a function of the trans-epithelial osmotic gradient across the CSF-secreting choroid plexus, we determined the rate of CSF secretion in anesthetized rats during experimentally-inflicted modulation of the ventricular osmolality. The CSF secretion rate was determined with the ventriculo-cisternal perfusion technique, in which a dextran-based aCSF is infused into the right lateral ventricle of the rat brain, while collecting fluid from cisterna magna simultaneously [15]. Since the employed dextran, with its large molecular weight (Mw: 150,000), barely penetrates the ventricular walls at the employed time scale (Fig. 1a), the dextran dilution largely corresponds to newly formed CSF. As it is well established that the CSF secretion rate relies on a range of physiological parameters, such as blood pressure, heart rate, blood oxygenation, type of anesthesia etc., the experimental procedures were carried out with proper mechanical ventilation of the animal and monitoring of a range of physiological parameters, following determination of the optimal anesthesia regime and verification of stable blood electrolyte content and osmolality (see Additional file 1, Fig. S1 and "Methods" section). The rate of CSF secretion in adult (9-week-old) male Sprague Dawley rats was obtained by infusing heated and equilibrated dextran-containing aCSF (with matching osmolality to that of rat CSF) into the lateral ventricle and recording the dextran content in the fluid collected from cisterna magna, see Fig. 1b for a representative

(See figure on next page.)

**Fig. 1** Negligible osmotic contribution to CSF secretion. a Demonstration of dextran levels after an ended ventriculo-cisternal perfusion experiment in a rat. Representative sagittal cryostat sections of brains displaying the injected lateral ventricle (dotted line) and DAPI stained choroid plexus and parenchymal cells. A droplet of dextran with the concentration present within the ventricles during the experimental procedure was placed on the coverslip (red circle) and served as reference intensity. LV: lateral ventricle, dex: dextran. It is evident that the dextran had not diffused into the brain parenchyma to any detectable extent during the experimental procedure. b Representative graph of the ratio of dextran (outflow/ inflow) during a 1 h control ventriculo-cisternal perfusion performed in a rat. Inset denotes the average CSF production rate in control rats, n = 28. c CSF production rate in rats subjected to varied trans-choroidal osmotic gradients by ventricular infusion of aCSF of osmolalities of ±100 mOsm (compared to aCSF), expected to be diluted 1:1 with newly formed CSF. Each dot represents one rat, n = 11. The slope was determined from linear regression analysis (R\(^2\) = 0.48) on the slope obtained based on the 11 rat experiments (slope significantly different from 0, P < 0.005). d Mean arterial pressure (AP) in rats subjected to ventriculo-cisternal perfusion upon ventricular infusion of aCSF with ±100 mOsm (mannitol), providing an expected ventricular osmolality of ±50 mOsm. Data are presented as the AP (in %) at the end of the experiment compared to the initial AP measurement, n = 3, paired t-test. e CSF secretion rates obtained from ventriculo-cisternal perfusion of rats upon elevated (~50 mOsm) ventricular osmolality with either mannitol or NaCl as the osmotic agent, n = 5. One-way ANOVA followed by Tukey’s multiple comparisons test, NS = not significant. f Required osmotic gradient to sustain a CSF production rate of 6.8 μl min\(^{-1}\) given the osmotic water permeability of the choroid plexus: Osmolality of CSF should exceed that of blood with ~280 mOsm. g–i Osmolality of blood (plasma or serum) and ventricular (V) or lumbar (L) cerebrospinal fluid from rats, n = 5 (g), pigs, n = 7 (h) and humans, n = 14 (i). Paired two-tailed t-test, NS = not significant.
experiment and inset for the summarized CSF secretion rate (6.8 ± 0.3 µl min⁻¹, n = 28).

To determine the CSF secretion rate as a function of the osmotic gradient across the choroid plexus, CSF secretion was measured with varying osmolality of the infused aCSF (up to ±Δ100 mOsm of that of the plasma osmolality with a predicted 1:1 dilution with the native CSF; ±Δ50 mOsm). The rate of CSF secretion increased slightly in response to increasing ventricular osmolality (Fig. 1c). Each mOsm elevation in the ventricular aCSF led to a 0.4% increase in CSF secretion rate (0.023 ± 0.008 µl × min⁻¹ × mOsm⁻¹, P < 0.05) with no effect of altered ventricular osmolality on the mean arterial blood pressure (in % of the value at the initiation of the experiment: +50 mOsm = 93 ± 4% (P = 0.19), −50 mOsm = 99 ± 4% (P = 0.84), n = 3 of each, Fig. 1d).

To retain the ionic composition of the aCSF in this series of experiments, the aCSF osmolality was adjusted with...
addition or removal of mannitol from the isosmotic control solution (as an inert osmolyte, see "Methods" section). The CSF secretion rate was similar whether the hyperosmolar challenge arose from addition of mannitol (8.0 ± 0.4 µl min⁻¹) or NaCl (7.2 ± 0.7 µl min⁻¹, n = 5 of each P = 0.55, Fig. 1e).

To obtain the passive osmotic water permeability of the rat choroid plexus epithelium, we assessed the cross-sectional surface area of the choroid plexuses (lateral and 4th) based on their wet-weight. 88% of the choroidal weight has been estimated to consist of epithelium [47], which gives 4.6 ± 0.4 mg choroid plexus epithelium per rat (n = 5). The choroidal volume thus approximates 4.6 × 10⁻⁹ cm³, assuming a cell density of 1 g cm⁻³ [48].

Given a cell height of ~ 10 µm [49], the cross-sectional area of (lateral and 4th) choroid plexus was 4.6 cm², which aligns with [47] upon age correction of the rats [50]. Taken together with the CSF secretion rate as a function of the osmotic gradient (0.023 ± 0.008 µl × min⁻¹ × mOsm⁻¹, Fig. 1c), the passive, trans-epithelial water permeability of the rat choroid plexus yields an Lp = 8.7 × 10⁻⁵ cm s⁻¹ Osm⁻¹. If the CSF should be produced entirely from conventional osmotic driving forces with the given osmotic water permeability, the theoretical ventricular osmolality required to drive the basal CSF secretion rate of 6.8 µl min⁻¹ can be calculated to ~ 280 mOsm higher than that of the plasma (= ~590 mOsm, Fig. 1f).

Absence trans-choroidal osmotic gradient

Based on the theoretical requirement for a large ventricular osmolality to drive CSF production of the given rate by conventional osmotic water flux, we determined the trans-epithelial osmotic gradient across the rat choroid plexus epithelium. To limit confounding alterations in electrolyte content (and thus osmolality), the experimental procedures were designed to limit the time from anesthesia induction to CSF/blood sample collection. With the swift protocol, we obtained osmolalities of 306 ± 4 mOsm for plasma and 307 ± 2 mOsm for CSF (sampled from cisterna magna; n = 6, Fig. 1g). The osmolality of these fluids surrounding the choroid plexus is thus equivalent (P = 0.78), illustrating that there is no trans-choroidal osmotic gradient to drive CSF secretion in rats. To verify this observation in a larger animal, we determined the osmolality of ventricular CSF (collected from cisterna magna) and blood extracted from anesthetized and mechanically ventilated pigs. The osmolality of pig blood (290 ± 1 mOsm) and CSF (291 ± 2 mOsm) was similar (n = 7, P = 0.22, Fig. 1h), as was the case for serum (293 ± 2 mOsm) and lumbar CSF (296 ± 2 mOsm) collected from healthy human individuals screened, but subsequently cleared for, normal pressure hydrocephalus (n = 14, P = 0.09, Fig. 1i). Note that regular anti-coagulant (EDTA)-coated blood sample tubes produce an elevation of the blood osmolality (Additional file 1: Fig. S3).

All blood samples were therefore collected either in the absence of anticoagulants (human) or in the presence of heparin (rat and pig), which did not significantly alter the plasma osmolality (Additional file 1: Fig. S3a, b). In summary, the osmolality of the bulk CSF is not elevated above that of the blood in either of the tested species. The osmotic gradient across the choroid plexus epithelium in vivo is thus orders of magnitude too small to drive CSF secretion by conventional osmosis.

CSF secretion against osmotic gradients

It is evident from Fig. 1c that increased ventricular osmolality slightly elevates the rate of CSF secretion. However, the left side of the graph depicts an experimental scenario in which the plasma osmolality is higher than that of the CSF. Under these conditions, the osmotic gradient would favor fluid flow from the ventricles to the vasculature. Nevertheless, CSF secretion continues, even when the choroid plexus faces an oppositely directed osmotic gradient of approximately 50 mOsm, a condition under which the CSF secretion is reduced a mere 20%. This finding illustrates that CSF can be secreted independently of, and even against, a sizeable bulk osmotic gradient. Taken together with the lack of a detectable osmotic gradient across the choroid plexus epithelium and its low trans-epithelial osmotic water permeability, we conclude that the CSF secretion must occur by mechanisms other than conventional osmotic water transport.

Local osmotic gradients cannot explain CSF secretion

The luminal surface membrane of the cuboidal-to-columnar choroid plexus epithelium is covered by abundant microvilli, which serve to increase the luminal surface area. The inter-microvillar space might serve as a protected area where solutes transported across the epithelium accumulate and create a local osmotic gradient driving fluid across the tissue even in the absence of an osmotic gradient in the bulk solutions surrounding the epithelial cell membrane. To determine if such a mechanism could account for the ability of the choroid plexus to secrete CSF in the absence of a bulk osmotic gradient, we created a mathematical model of solute-linked water transport in the inter-microvillar space of the luminal membrane of the choroid plexus.

To obtain the anatomical parameters of choroid plexus from rats of the species and age employed for the physiological experiments, we conducted morphometric analysis following transmission and scanning electron microscopy of the acutely extracted tissue. Scanning electron microscopy reveals the gross structure of part of the choroid plexus (Fig. 2a); at higher magnification,
individual tissue fronds are seen to be covered by an irregular epithelium with abundant microvilli on the luminal surface (length $1.71 \pm 0.09 \, \mu m$, $n=45$ from ten different cells, Fig. 2b, c). The microvilli are typically cylindrical at the base (radius $0.06 \pm 0.01 \, \mu m$, $n=13$) but increase in diameter towards the tip to end in a small bulb (radius $0.12 \pm 0.01 \, \mu m$, $n=8$; see arrows in Fig. 2b–d). The extent of the brush border is somewhat smaller (approximately 1.5 $\mu m$) than the length of microvilli because of their flexibility and interdigitation (Fig. 2b, c). The spatial density of microvilli was estimated from the linear density on TEM images (Fig. 2e) to be 18 microvilli per $\mu m^2$, which altogether increased the surface area of the luminal membrane 12-fold. With the 4.6 $cm^2$ apparent luminal surface obtained above, the estimated true membrane area arrives at 57 $cm^2$ in the 9-week-old Sprague Dawley rat.

For the model, we used the simplified anatomic representation shown in Fig. 2f–j. We assumed that all solutes in the ventricular CSF enter through the inter-microvillar space, likely overestimating the local osmotic gradient, and that the solutes are removed by bulk CSF drainage at the same rate as they enter. Given an isotonic CSF secretion rate of $6.8 \, \mu l \, min^{-1}$, a bulk CSF osmolality of 307 mOsm (Fig. 1g), and a CSF density of 1.00 g ml$^{-1}$ [51], the ion transfer rate across the entire luminal membrane amounts to $3.48 \times 10^{-5} \, mmol \, s^{-1}$ (see Additional file 2). Our model only accounts for the luminal membrane, but the trans-choroidal osmotic water permeability obtained above includes the effect of the two epithelial membranes. Each membrane’s osmotic water permeability is double the measured value, since the membranes are configured in series. Accordingly, the osmotic water permeability of the luminal membrane (true area) was calculated to be $1.4 \times 10^{-5} \, cm \, s^{-1} \, Osm^{-1}$. With these values, our model predicts that inter-microvillar local osmotic forces may account for less than 0.1% of the observed CSF secretion rate ($0.004 \, \mu l \, min^{-1}$ of the measured $6.8 \, \mu l \, min^{-1}$). Our mathematical model thus suggests that CSF secretion does not originate from local osmotic gradients built up between the choroidal microvilli.
Choroidal transport proteins in the luminal membrane

RNaseq on the rat choroid plexus identified highly expressed electrolyte transporters in choroid plexus that could contribute to ion and fluid secretion across the luminal membrane: the Na⁺/K⁺-ATPase (α1), NKCC1, and the bicarbonate transporter NBCe2 all appeared in the top 6% highest expressed transcripts encoding plasma membrane ion transporters: The Na⁺/K⁺-ATPase subunit α1 ranked as number 4 (TPM = 516; represents ~4% of all plasma membrane transporters in choroid plexus), NBCe2 ranked as number 5 (TPM = 504; represents ~4% of all transporters in choroid plexus), and NKCC1 as number 13 (TPM = 230, represents ~2% of all transporters in choroid plexus) out of a total of 233 transcripts encoding choroidal plasma membrane ion transporters (Fig. 3a). The Na⁺/H⁺ exchanger NHE1 appeared further down the rank list (number 131 out of 233 transcripts, with a TPM = 7; represents ~0.05% of all transporters in choroid plexus). These findings were essentially verified with qPCR, although with a slightly lower, but still robust, expression of NBCe2 in the lateral choroid plexus (Fig. 3b) and in the 4th choroid plexus (Additional file 1: Fig. S4a).

The NKCC1, NBCe2, NHE1, and Na⁺/K⁺-ATPase (α1) localize to the luminal choroidal membrane in all tested species [52–56], here verified for NKCC1 in the rat choroid plexus (Additional file 1: Fig. S4b). The α1 subunit of the Na⁺/K⁺-ATPase is the dominant catalytic subunit in choroid plexus, with the α2 and α3 transcripts appearing at much lower levels (Fig. 3c and Additional file 1: Fig. S4c). The high β1 transcript level suggests this accessory subunit as the dominant, although both β3 and, to a lesser extent, β2 are expressed in the lateral choroid plexus (Fig. 3c and Additional file 1: Fig. S4c) and may serve to modulate the pump function [57]. Notably, the abundance of Na⁺/K⁺-ATPase α1 protein is threefold higher in choroid plexus than in brain parenchyma, whereas the glial α2 and the neuronal α3 subunits [57] are practically
absent in choroid plexus at the protein level (Fig. 3d, e, and Additional file 1: Fig. S4d).

**Contribution of transporters to CSF secretion**

Quantification of the individual contribution to CSF secretion of these luminally expressed transport mechanisms was obtained with a pharmacologic strategy (Fig. 4a). Efficient and well-established inhibitors exist for NKCC1 (bumetanide), the Na⁺/K⁺/2Cl⁻ transporter (ouabain), and NHE1 (cariporide), but the bicarbonate transporters are notoriously difficult to inhibit specifically and drug potencies not well defined. Prior to initiating the ex vivo and in vivo experimentation, we therefore determined the inhibitor concentration profile of the NBC inhibitors DIDS [58] and S0859 [59], the latter employed in LI-COR experiments and [Na⁺]i determinations due to DIDS’ autofluorescence in these spectra. To this end, rat NBCe2 was expressed heterologously in *Xenopus laevis* oocytes and its activity monitored by two-electrode voltage clamp. NBCe2-mediated membrane currents were abolished with 30 µM S0859 (IC₅₀ of 10.7 ± 0.9 µM, n = 9, Additional file 1: Fig. S5a–c) and with 300 µM DIDS (IC₅₀ = 4.5 ± 1.8 µM, n = 6, Additional file 1: Fig. S5d–f).

To determine the quantitative contribution of the luminaly expressed transport proteins to CSF secretion, the ventriculo-cisternal perfusion method was employed on anesthetized rats with inclusion of the various inhibitors. To obtain high level of fidelity, each rat served as its own control. Figure 4b illustrates a time control experiment, in which the infused aCSF was replaced with an identical solution when the dextran dilution had stabilized (1 h) and the CSF secretion rate thus reliably monitored. The CSF secretion rate remained stable over the 2 h experimental window (Fig. 4b, c). With an expected ventricular dilution of at least 1:1 of the intraventricularly infused inhibitor concentrations in the ventriculo-cisternal perfusion, the inhibitor concentrations of the infused aCSF were adjusted to increase the probability of targeting the candidate transport mechanisms in both lateral choroid plexuses, in addition to the downstream 3rd and 4th choroid plexus. We thus expect maximal ventricular drug concentrations of 50 µM bumetanide, 2.5 mM ouabain, 50 µM cariporide, and 750 µM DIDS, but with lower concentrations near the (contralateral) choroidal surfaces. Each rat served as its own control with introduction of inhibitor (or vehicle) at a point of stable baseline. The CSF secretion was reduced by 36 ± 4% with NKCC1 inhibition (bumetanide; n = 7, P < 0.001), 49 ± 2% with Na⁺/K⁺-ATPase inhibition (ouabain; n = 6, P < 0.001), 28 ± 4% with NBCe2 inhibition (DIDS; n = 4, P < 0.001), but unchanged with NHE1 inhibition (cariporide; n = 5, P = 1.0, Fig. 4c, d).

Several of these transporters may be directly or indirectly implicated in setting the blood pressure, alteration of which could indirectly affect CSF secretion. The mean arterial blood pressure was therefore recorded in parallel with the ventriculo-cisternal perfusion. The blood pressure (prior to inhibitor infusion) was 67 ± 1 mmHg, n = 21. After infusion of the inhibitor, the blood pressure was (in % of own control) 97 ± 2 for bumetanide (n = 7, P = 0.13), 94 ± 4 for ouabain (n = 5, P = 0.16), 98 ± 2 for DIDS (n = 4, P = 0.31), and 102 ± 3 for cariporide (n = 5, P = 0.47) (Fig. 4e) and, thus, remained stable during the procedure.

Although inhibition of these ubiquitously expressed transport mechanisms did not alter the mean arterial blood pressure, they, upon longer experimental regimes, could penetrate the brain parenchyma and indirectly affect CSF secretion in unpredictable manners. For swifter recordings of the CSF dynamics with a less-invasive approach, we took advantage of the LI-COR Pearl Trilogy small animal imaging system [15]. This procedure

(See figure on next page.)

**Fig. 4** Three transporters as key contributors of CSF secretion. a Illustration of the luminal ion transport proteins: NBCe2, NKCC1, NKA, and NHE1 in choroid plexus (grey) and their inhibitors DIDS/S0859, bumetanide, ouabain, and cariporide. CSF is shown in blue. b Representative time control experiment with ventriculo-cisternal perfusion in rats depicting the ratio of dextran (outflow/inflow) as a function of time with a solution change to an identical solution. c Quantification of the CSF production rate by ventriculo-cisternal perfusion in rats treated with intraventricularly-delivered inhibitors of NKCC1 (bumetanide; n = 7), NKA (ouabain; n = 6), NHE1 (cariporide; n = 5), NBCe2 (DIDS; n = 4) or control solution (n = 7) at solution change (grey box). d Summarized data obtained after 35–55 min of inhibitor/vehicle exposure, with statistical significance determined by one-way ANOVA, followed by Dunnett’s multiple comparisons test. Asterisks denote difference from control condition (vehicle). ***P < 0.001, NS = not significant. e Mean arterial blood pressure (AP) obtained during the ventriculo-cisternal perfusion experiments is illustrated before and after (55 min) intraventricular exposure of the pharmacological inhibitors. Statistical significance was determined with paired t-test. NS = not significant. f Illustration of IRDye 800 CW carboxylate dye injected in the right lateral ventricle shown in pseudo-colors superimposed on a white light image of the rat. The dye intensity is quantified as a function of time in the white box placed at lambda (left panel). Right panel illustrates a superimposed image of ventricular fluorescence on a white light image of a rat brain cut in the midsagittal plane after ended live imaging. The intensity scale is in arbitrary units. g Representative images of the dye content at T0.5 min and T5 min after placement in fluorescent scanner in control rats (Ctrl) or bumetanide-treated rats (Bum). h Live imaging of intraventricular IRDye 800 CW carboxylate dye following treatment with bumetanide (NKCC1 inhibition, n = 5), ouabain (NKA inhibition, n = 5), or S0859 (NBCe2 inhibition, n = 6) or control (vehicle) solution (n = 8). Inset: control: 0.12 ± 0.01 a.u. min⁻¹, n = 7, vs. cariporide (NHE1 inhibition): 0.12 ± 0.02 a.u. min⁻¹, n = 6. i Quantification of the dye flow rate determined from linear regression analysis of h over the 5 min with statistical significance determined by one-way ANOVA followed by Dunnett’s multiple comparisons test. Asterisks denote difference from control condition, ***P < 0.001, *P < 0.05.
Fig. 4 (See legend on previous page.)
allows for visualization of the two-dimensional rostral to caudal movement of fluorescent dye injected into the ventricles of the anesthetized rats within minutes of injection (Fig. 4f, left panel, for verification of the dye reaching the ventricular system, see Fig. 4f, right panel). The initial movement of the dye from the lateral ventricle into the region of interest (Fig. 4f, g) was quantified by linear regression (Fig. 4h) and employed as a proxy for CSF production (although a component is attributed to dye diffusion). After inclusion of the various inhibitors, the rate of control dye movement (0.16 ± 0.18 a.u. min⁻¹, n = 8) was reduced by 39% with NKCC1 inhibition (bumetanide: 0.10 ± 0.01 a.u. min⁻¹, n = 5), 62% with Na⁺/K⁺-ATPase inhibition (ouabain: 0.06 ± 0.01 a.u. min⁻¹, n = 5), and 35% with NBCe2 inhibition (S0859: 0.11 ± 0.01 a.u. min⁻¹, n = 6) (Fig. 4h, i). Inhibition of NHE1 had no effect on the CSF flow (control: n = 7, cariporide: n = 6, P = 0.75, Fig. 4h inset). These results qualitatively mimic those obtained with the ventriculocisternal perfusion method and indicate that the Na⁺/K⁺-ATPase, NKCC1, and NBCe2 transporters contribute significantly to CSF secretion. Taken together, these data suggest that inhibition of individual choroidal transporters, the Na⁺/K⁺-ATPase, NKCC1, and NBCe2, affects the rate of CSF secretion in a direct manner, while NHE1 did not contribute to this fluid secretion.
Quantification of choroidal Na⁺ efflux
To rule out any indirect effect of these pharmacological inhibitors, we took advantage of the CSF secretion being correlated with the net flux of Na⁺ across choroid plexus [60]. To fashion an experimental design with which to quantify each candidate transporter’s contribution to the choroidal net efflux of Na⁺, as a proxy of CSF secretion, we employed acutely excised choroid plexus tissue loaded with the Na⁺-sensitive fluorescent dye SBFI (Fig. 5a). The [Na⁺]i dynamics were monitored by wide-field SBFI imaging upon acute application of the transport inhibitors. Baseline SBFI ratio, and consequently [Na⁺]i, were stable for prolonged periods (up to 40 min) if no other manipulation was performed (not shown). The SBFI dynamics demonstrated an immediate increase in [Na⁺]i upon inhibition of NKCC1 (20 μM bumetanide: 0.034 ± 0.005 a.u. min⁻¹, n = 7, P < 0.01). Notably, an earlier study showed that in Bergmann glial cells, application of bumetanide had the opposite effect, resulting in a decrease in [Na⁺]i, indicating opposite direction of NKCC1 in the two preparations. Choroid plexus [Na⁺]i also increased upon inhibition of the Na⁺/K⁺-ATPase (2 mM ouabain: 0.022 ± 0.004 a.u. min⁻¹, n = 6, P < 0.01), or NBCe2 (30 μM S0859: 0.023 ± 0.006 a.u. min⁻¹, n = 5, P < 0.05), while the [Na⁺]i remained stable upon NHE1 inhibition (10 μM cariporide: 0.002 ± 0.001 a.u. min⁻¹, n = 6, P = 0.07, Fig. 5b, c). This inhibitor-mediated [Na⁺]i elevation in choroid plexus epithelial cells demonstrates that NKCC1, the Na⁺/K⁺-ATPase, and NBCe2 work in the direction promoting Na⁺ efflux across the luminal membrane of choroid plexus. Verification of NHE1 protein expression in rat choroid plexus was demonstrated with Western blotting (Fig. 5d). The functional luminal membrane localization of NHE1 was visualized with fluorescence-based pH monitoring of choroid plexus challenged with an acid load in standard HCO₃⁻-aCSF containing 5 mM NH₄Cl [62], the return of which was delayed in presence of the NHE1 inhibitor cariporide (Fig. 5e, f). Taken together, the complementary in vivo and ex vivo data illustrate key roles for NKCC1, NBCe2, and the Na⁺/K⁺-ATPase in CSF secretion across the luminal membrane with no observed contribution from NHE1 in CSF secretion.

Outward-directed NKCC1, not KCC, transport
NKCC1’s ability to contribute directly to CSF secretion via its ability to transport water hinges on its transport being outwardly-directed. To resolve the NKCC1 transport direction, we determined the choroidal ⁸⁶⁸Rb⁺ efflux rate constant in acutely isolated, ⁸⁶⁸Rb⁺-loaded, rat choroid plexus. ⁸⁶⁸Rb⁺ can replace K⁺ at its binding site and thus act as a tracer for the K⁺ transport. The ⁸⁶⁸Rb⁺ efflux rate constant from rat choroid plexus was diminished by ~ 60% in the presence of bumetanide (0.40 ± 0.02 min⁻¹ in control, n = 7, vs. 0.15 ± 0.01 min⁻¹ in bumetanide, P < 0.001, n = 5, Additional file 1: Fig. S6a), demonstrating the bumetanide-sensitive outward flux of ⁸⁶⁸Rb⁺. NKCC1-mediated K⁺ efflux was verified in acutely isolated pig choroid plexus, in which inclusion of bumetanide led to a 68% decrease of ⁸⁶⁸Rb⁺ (K⁺) release (control: n = 6, bumetanide: n = 7, P < 0.001, Additional file 1: Fig. S6b). Different isoforms of the related K⁺/Cl⁻ cotransporters have been proposed to be expressed in the choroid plexus and potentially contribute to CSF secretion [14, 63, 64]. Semi-quantification of their transcripts in rat choroid plexus by qPCR demonstrated expression of KCC1, albeit at lower levels than that of NKCC1, whereas the transcript levels of KCC2-4 were near/below detection range (Additional file 1: Fig. S6c). The expression of NKCC1 and KCC1, and absence of other KCCs, was verified at the protein level in rat and pig choroid plexus by Western blotting (Additional file 1: Fig. S6c, inset and 6d). To determine whether functional KCC expression occurred in the luminal membrane of choroid plexus, we included furosemide, a common blocker of NKCC1 and KCCs, in the ⁸⁶⁸Rb⁺ efflux assays. The inhibitory potential of furosemide did not exceed that of bumetanide in choroid plexus from both rat and pigs (Additional file 1: Fig. S6a, b). Taken together, these findings identify NKCC1 as an outwardly-directed transport mechanism in acutely isolated choroid plexus from rats and pigs, and demonstrate a lack of KCC activity at the luminal membrane in this tissue.

NKCC1-mediated transport of water
To demonstrate NKCC1-mediated choroid plexus volume changes, representing movement of water, isolated rat choroid plexus was loaded with the fluorescent probe calcein-AM and exposed to an osmotic challenge of different osmolytes during live imaging. Exposure of the tissue to aCSF containing an additional 100 mOsm led to abrupt shrinkage of the choroid plexus tissue when the osmotic challenge was generated by addition of mannitol (−0.9 ± 0.1% s⁻¹, n = 5, P < 0.001) or NaCl (−0.7 ± 0.0% s⁻¹, n = 5, P < 0.001, Fig. 6a). In contrast, a 100 mOsm hyperosmotic challenge with KCl as the osmolyte induced instant swelling of the choroid plexus (0.4 ± 0.1% s⁻¹, n = 5, P < 0.01), with no detectable delay (Fig. 6a). Application of the NKCC1 inhibitor bumetanide abolished the KCl-mediated volume increase of the choroid plexus, which then responded to the osmotic challenge with a shrinkage (−0.8 ± 0.1% s⁻¹, n = 5, P < 0.001) comparable to that obtained with the two other osmolytes (Fig. 6a). With the excessively elevated [K⁺]o, the NKCC1 became inwardly directed and transported its solutes and water into the choroid plexus tissue, thereby demonstrating the biophysical ability of the transporter to
promote tissue swelling even when the choroid plexus faced an osmotic gradient promoting outward water flux. NKCC1-mediated water transport can thus promote fluid movement in choroid plexus independently—and even against—a bulk osmotic gradient.

NKCC1 inhibition lowers ICP
To test whether the CSF secretion can directly modulate the ICP, we measured the ICP epidurally in anesthetized and ventilated rats while mimicking a hypersecretion of CSF. The basal ICP was 4.3 ± 0.4 mmHg, n = 10, prior to infusion of aCSF and remained stable during the experimental window with a slow infusion of aCSF (0.5 μl min⁻¹) into one lateral ventricle (102 ± 5% of ICP prior to initiation of infusion, n = 6, P = 0.74, Fig. 6b). Mimicking a 25% increase in basal CSF secretion by an enhanced infusion rate of aCSF (1.5 μl min⁻¹), we observed an elevated ICP (122 ± 4% of ICP prior to initiation of infusion, n = 4, P < 0.01, Fig. 6b). This demonstrates that mimicked CSF hypersecretion directly affected the ICP. To test if reduction of CSF secretion, likewise, could modulate the ICP, we infused bumetanide-containing aCSF into the lateral ventricle of anesthetized and ventilated rats while measuring the ICP.

Fig. 6 NKCC1-mediated fluid flow and contribution to ICP. a) Calcein fluorescence in rat choroid plexus as a function of time with exposure to control aCSF or + 100 mOsm aCSF adjusted with mannitol, NaCl, or KCl in the absence or presence of bumetanide, when indicated by grey box, n = 5. Summarized data illustrated in right panel with statistical significance tested with one-way ANOVA followed by Tukey’s multiple comparison test, **P < 0.01, ***P < 0.001, NS: not significant. b) ICP recordings during intraventricular infusion of aCSF at rates of 0.5 (n = 6) or 1.5 μl min⁻¹ (n = 4) over 20 min. Unpaired two-tailed t-test was applied to evaluate statistically significant differences at the end of the procedure. c) The intracranial pressure of rats treated with slow intraventricular infusion (0.5 μl min⁻¹) ± bumetanide for 100 min. Controls are from b, n = 6. Data are presented as % of control ICP as a function of time with each dot representing the mean value over a 5 min period. The endpoints are demonstrated in the right panel with unpaired two-tailed t-test employed for statistical analysis, **P < 0.01.
Infusion of vehicle-containing aCSF (0.5 μl min⁻¹) did not significantly change the ICP over the 100 min duration of the experiment (11 ± 4% reduction, n = 6, P = 0.1), whereas infusion of bumetanide-containing aCSF led to a pronounced decrease in the ICP (of 29 ± 2%, n = 6, P < 0.01, Fig. 6c). These findings provide a proof-of-principle that pharmacological inhibition of CSF secretion can indeed promote a decline in the ICP.

Discussion
Here, we present evidence that the CSF production is not driven primarily by conventional osmosis. We observed a low trans-epithelial water permeability of the rat choroid plexus in vivo, no detectable osmotic gradient across the tissue, minor contribution from local inter-microvillar standing gradients, and a unique capability to transport fluid against osmotic forces in the bulk solution. Instead, of conventional osmosis, we propose that CSF, at least in part, is formed by transporter-mediated water transport, which is geared to function in the absence of a trans-epithelial bulk osmotic gradient. The cotransporters NKCC1, NBCe2, and the Na⁺/K⁺-ATPase in the luminal membrane of choroid plexus appeared as key contributors to CSF secretion in rats. By abolishing the NKCC1-mediated fraction of the CSF secretion, we obtained experimental proof-of-concept that this molecular target could serve to control and reduce the ICP in rats; this may constitute a first step towards a needed efficient and targeted treatment option for patients with disturbed brain fluid dynamics and elevated ICP.

CSF secretion is generally assumed to be entirely osmotic: water is driven from the blood into the ventricles by a sufficiently large osmotic gradient across a sufficiently water-permeable epithelium. The presence of AQP1 in the luminal membrane has served as support for this model [65, 66]. Genetic deletion of AQP1, however, reduced the CSF production by only 20% in mice [65], part of which could originate from the 80% drop in the central venous pressure of these mice upon systemic AQP1 deletion [65]. In alignment with the lack of substantial AQP expression in the basolateral membrane of choroid plexus, we obtained a low trans-epithelial osmotic water permeability of the rat choroid plexus (estimated Lₚ = 9 × 10⁻⁵ cm s⁻¹ Osm⁻¹ per apparent choroid plexus area, similar to that observed in rabbit choroid plexus [67]). This value would be approximately one magnitude lower if the true membrane area is employed, see Additional file 2. It should be noted that the ependymal lining of the ventricles are not expected to contribute significantly to the osmotic water flux induced by ventricular perfusion of aCSF with varying osmolality, as the ependymal cell lining does not confer the barrier property required to represent the semi-permeable membrane necessary to sustain osmosis, due to their lack of tight junctions [68, 69]. With the ventricular osmotic: water is driven from the blood into the ventricle and quantification of the CSF exiting the brain via a cannula placed in the lateral ventricle [26, 40]. This 'direct' method arrives at CSF secretion rates significantly lower than that obtained by the ventriculo-cisternal perfusion assay. Although the 'directly obtained' secretion rate would be expected to be significantly higher if the contribution from the large 4th choroid plexus [3] was included and/or the anaesthetized animals were ventilated during the experimental procedure [15], the lower CSF secretion rate obtained by this procedure suggests a...
theoretical requirement for lower ventricular osmolality to sustain CSF secretion by pure osmosis. However, no osmotic gradients were detected in our experimental rats and pigs, nor in humans (this study and [76]). Other animal studies report a slightly increased ventricular hyperosmolality of ~ 5 mOsm [77–80]. This discrepancy could arise from experimental or technical differences such as a prolonged window between animal death and the sample extraction, pre-treatment of animals with saline before sampling [78, 79], or artifacts from improper pre-analytical handling (e.g., freezing of CSF and/or ruptured blood cells in the centrifuged CSF). It should be noted that such a small osmotic difference could supply a sufficient rate of osmotically induced water flux, provided the epithelium has an osmotic water permeability in the order of that of the proximal tubule with its robust AQP expression on both epithelial aspects [81].

Although our findings indicate that conventional osmosis may not be the sole driver of CSF secretion in physiology, they do not preclude that a continuously delivered intraventricular osmotic challenge can promote ventriculomegaly, as observed in experimental rats [82, 83] and suggested to underlie some forms of hydrocephalus [84]. More notably, CSF secretion occurred even when a bulk osmotic gradient favoring fluid flow from the ventricles to the blood stream was imposed across the choroid plexus. CSF secretion occurred against gradients as large as ~ 50 mOsm, which corresponds to an osmotic pressure 10 times higher than the blood pressure. Such continued fluid secretion in the face of an oppositely-directed bulk osmotic gradient has previously been observed, but not explained, in different animal species, i.e. cats and goats, and with different osmolytes, whether introduced into the vasculature or directly into the ventricular compartment [72, 73, 85, 86]. This observation suggests that a mode of water transport different from conventional osmosis could contribute to the sustained fluid flux across the choroid plexus epithelium.

Various models of how trans-epithelial isotonic fluid transport may occur in the absence of measurable osmotic gradients have been proposed over the years, as comprehensively reviewed by Damkier and colleagues [14]. Some of these models rely on water and ion permeability of the tight junctions supporting the isotonic fluid transport [14]. With the tight junctions encompassing only a slight fraction of the epithelial membrane, these junctions must have excessively large unit water permeability to sustain the measured fluid flow [87]. With such high unit water permeability, the anticipated size of these pores is difficult to reconcile with their impermeability to the electrolytes required to generate the osmotic gradient. The resulting low, or non-existing, reflection coefficient represents a challenge for the model of tight junction-based osmotic water transport [87]. Other models rely on local osmotic gradients arising in flow-protected compartments within the basolateral spaces between epithelial cells [14]. Their existence was proposed [29, 88], but could not be experimentally demonstrated [89, 90], for review, see [3]. CSF secretion across the choroid plexus takes place from the basolateral to the luminal side with the junctional complexes located at the luminal border and the luminal membrane covered with (1–3 μm) microvilli (this study and [91, 92], some terminating in a bulbous structure (this study and [93])). This reversed anatomical organization provides poor support for a local build-up of osmolytes (standing gradients and unstirred layers [29, 88]) in intercellular diffusion-restricted spaces, since these appear on the opposite side of the choroidal epithelium [3, 14, 20, 87]. To evaluate if local osmotic gradients could arise between the microvilli of the choroid plexus and drive fluid flow, we performed mathematical modelling of this process. With the employed parameters, including the CSF secretion rates obtained in the present study, the model assigned < 0.1% of the CSF secretion to local osmotic forces between the choroidal microvilli. Employing the lower CSF secretion rate suggested by the ‘direct method’ of CSF secretion [26], the model assigned the same < 0.1% of the CSF secretion to such local osmotic forces. Such lack of osmotic particle build-up near the membrane surface is supported by ion concentration measurements in the vicinity of the choroidal microvilli brush border with ion-sensitive microelectrodes [94] and comparison of the osmolality of newly-formed CSF collected at the choroidal surface with that of bulk-collected CSF [95].

Cotransporter-mediated water transport may thus be a missing link supporting some of the CSF secretion in the absence of a trans-epithelial bulk solution osmotic gradient. NKCC1 and KCC belong to the growing number of cotransporters with the ability to mediate cotransporter-mediated water transport [17, 18, 96], for review, see [21, 97]. Such transporter-mediated ability to move water across the choroid plexus luminal membrane, independently of the bulk osmotic gradient, has been detected in mouse [15], rat (this study), and salamander [96] choroid plexus, the latter of which was assigned to KCC activity, rather than the NKCC1 observed in the rodents. This mode of water transport is observed with transporter-mediated substrate translocation alongside concomitant movement of a number of water molecules; a number that is independent of the osmotic gradient in the surrounding bulk solutions [97]. With the hyperosmotic transportate produced by these transporters [97], some contribution of conventional osmosis is expected to contribute to the net water flux across the choroid plexus and other cell membranes. Cotransporter-mediated transport...
water transport appears to take place via a process within the protein itself [19, 20, 97], the precise mechanisms of which remains elusive. A recent cryo-EM study of NKCC1 revealed 86 water molecules residing in its translocation pathway at the given conformation depicted in the structure [98]. This number of water molecules is incompatible with the earlier proposed occlusion model [20, 97, 98], which stipulated occlusion of the transported water molecules along with the transported substrates. However, such prominent number of water molecules in the substrate translocation pathway provides support for the suggested working model of cotransporter-mediated water transport that is based on a hyper-osmolar cavity. In this model, the substrate(s) is suggested to be held in a thermodynamically free state during its exit from its binding sites within the protein, and thereby builds up hyperosmolarity inside the exit cavity of the protein and subsequent fluid flow through the cotransporter protein (described in [20, 97], simulated in [19], and modelled in [99]). We anticipate future structural revelations of distinct conformational states of these transport proteins and subsequent molecular dynamics simulations thereof to provide mechanistic insight into the currently unresolved molecular mechanisms underlying cotransporter-mediated water transport.

NKCC1 and KCC1, but neither of the KCC2-4 isoforms, were expressed at the mRNA and protein level in choroid plexus of rats and pigs, in accordance with other studies [15, 100–102], but conflicting with studies detecting KCC3 or KCC4 in the choroid plexus [63, 64]. With no functional KCC expression in the luminal membrane of rat, pig, or mouse choroid plexus, NKCC1 alone acted on the CSF-facing side of choroid plexus with an outwardly-directed K\(^+\)-translocation (this study and [15, 35]). This unique transport direction is assigned to the high choroidal ion concentrations of Na\(^+\) and Cl\(^-\) [15], which determines the electrochemical gradient and thus the innate transport direction for a given protein. However, the NKCC1 transport direction may be reversed under certain circumstances such as during early development or in dissociated choroid plexus epithelial cells [92, 103, 104].

Detection and quantification of choroidal electrolyte transport mechanisms demonstrated the Na\(^+\)/K\(^+\)-ATPase catalytic subunit α1 in association with β1/β3 (and near-absence of the neuronal (α3) and glial (α2) isoforms) in addition to NKCC1 and NBCe2 amongst the highest expressed luminal electrolyte transport proteins in the choroid plexus, with lesser abundance of NHE1. These transport proteins have all been implied in CSF secretion in previous studies, see e.g. [15, 16, 60, 105–114] and [3, 14] for reviews, but their relative quantitative contribution has not been addressed in prior parallel studies. To reveal the relative contribution of each of these Na\(^+\)-coupled transporters to the CSF secretion across the luminal membrane, these transcriptional top hits of highly expressed electrolyte transporters were examined by in vivo determination of CSF secretion rates in rats by direct pharmacological inhibition. Quantification of their contribution to CSF secretion demonstrated robust contributions from the Na\(^+\)/K\(^+\)-ATPase, NKCC1, NBCe2, and none from NHE1, with absence of indirect effects arising from inhibitor-mediated cardiovascular changes. These findings were obtained with two different CSF secretion assays, the ventriculo-cisternal perfusion method and with the LI-COR bioimaging method that provides a proxy for the CSF dynamics, and underscored by the impact of these transporters on the intracellular [Na\(^+\)] homeostasis in the excised choroid plexus. Although the absolute CSF secretion rate may differ with the ventriculo-cisternal perfusion assay (here employed) and the ‘direct’ method [26], the fractional inhibition of the CSF secretion by inclusion of various inhibitors or osmotic challenges are not predicted to vary with the experimental approaches. Although, oddly, the ‘direct’ method requires infusion of aCSF containing 45 mM acetazolamide and 2.7 mM bumetanide [16, 26] to obtain the well-established reduction of CSF secretion and choroid plexus ion flux generally obtained with infusion of 50–100 times lower concentrations [15, 60, 108, 109, 115, 116]. Although NHE1 did not contribute to CSF secretion, its expression in the luminal membrane of choroid plexus [56] was confirmed and its functional role in CSF pH dynamics demonstrated. Inhibitors of the different transport proteins are envisaged to reach their target transport proteins in all CSF-facing structures, i.e., the ependymal cell lining or the leptomeninges insofar as these transport proteins might be expressed there. Accordingly, the CSF secretion assays are not exclusive to choroidal CSF secretion, although this site of origin appears to dominate [3]. Pharmacological approaches, as employed here, may be hampered by specificity issues, but they represent a clear advantage in the acuteness of their inhibitory action. Prolonged inhibition (or genetic deletion) of any of the implicated transport mechanisms may affect intracellular ion concentrations and/or pH. These predicted changes may indirectly affect neighbor transport mechanisms, and thus potentially add confounding elements to the experimental approach. The different, but complementary, technical approaches employed in this study (ventriculo-cisternal perfusion, LI-COR, [Na\(^+\)], measurements) produce experimental read-outs at distinct time scales (minutes to hours), and are based on both in vitro and in vivo experimentation, yet still produced similar results. Such alignment may facilitate drawing conclusions regarding the direct
implication of the tested transport proteins in these processes.

With the delineation of some luminal membrane transport mechanisms supporting CSF secretion, it now remains to determine the potential contribution of the many other channels and transporters detected in the choroid plexus [117] and to categorize the molecular pathways for water entry from the basolateral side of the choroid plexus. At this location reside the bicarbonate transporting mechanisms AE2 and NCBE [118], which rank as number 6 and 10 highest expressed choroidal plasma membrane transporters (of 233 transcripts) in the RNAseq data set obtained in this study, in contrast to the bicarbonate transporter NBCn1 with much lower abundance in the choroid plexus tissue (6 TPM). The importance of choroidal HCO3− transporters is evident from the ability of the carbonic anhydrase inhibitor acetazolamide to reduce CSF secretion [114, 115, 119], but their individual contributions remain elusive. Successful genetic deletion of select choroidal HCO3− transporters promoted a redistribution of other membrane transport mechanisms [56, 120], which prevented firm conclusions of the CSF secretion capacity of the genetically deleted transporters.

Elevation of ICP is generally anticipated to occur following blockage of CSF efflux routes. While such manner of ICP elevation certainly accounts for the majority of hydrocephalus cases, CSF hypersecretion, or mimicking thereof, may cause the damaging brain fluid accumulation observed in connection with a range of different pathologies (this study and [16]). Irrespective of the origin of the fluid accumulation, reduction of CSF secretion by pharmacological measures could be a future therapeutic route to lowering elevated ICP. Accordingly, acute inhibition from the intraventricular side of the choroidal transport mechanism NKCC1 implicated in CSF secretion reduced the ICP of healthy rats by 30%. Such decrease in bumetanide-mediated ICP reduction aligns well with this NKCC1 inhibitor preventing intraventricular hemorrhage-induced ventriculomegaly [16]. With the human choroidal expression of NKCC1 [121], this protein—or another of the choroidal transport proteins involved in CSF secretion—or their potential upstream regulatory signaling pathways could serve as a molecular target for therapeutic treatment of certain conditions with disturbed CSF dynamics.

In conclusion, we here propose that CSF secretion across the choroid plexus does not occur solely by conventional osmosis, whereby electrolytes are transported across the epithelium with osmotically obliged water entering via parallel routes. A trans-choroidal osmotic gradient could not be detected and the water permeability of the choroid plexus epithelium thus too low to support the well-established rate of CSF secretion. Local osmotic gradients arising in the inter-microvillar space do not appear to exist and/or suffice to support the CSF secretion. The ability of choroid plexus to continue CSF secretion even when faced with unfavorable osmotic gradients thus promotes cotransporters, and their ability to support water transport independently of the prevailing osmotic gradient in bulk solutions, as a contributing molecular mechanism supporting this pivotal fluid flow. Accordingly, we have illustrated the cotransporter NKCC1, the Na+/K+/ATPase, and the HCO3− transporter NBCe2 as key contributors to choroidal CSF secretion. Future research will, hopefully, reveal the molecular mechanisms underlying the cotransporter-mediated water transport, determine if the Na+/K+/ATPase and NBCe2 belong to the transport proteins capable of supporting such water flux, identify other potential local osmotic gradients that contribute to the CSF secretion, and quantify the contribution from different basolateral transport proteins sustaining the fluid movement from the interstitial space into the choroid plexus epithelium. The latter identification could promote the highly desired pharmacological targets accessible from the vascular compartment and aimed at reducing CSF secretion in the pathologies comprising brain fluid accumulation and elevated ICP.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12987-022-00358-4.

**Additional file 1.** Supplementary experimental data.

**Additional file 2.** Supplementary data for mathematical modelling.

**Acknowledgements**

We thank Trine Lind Deviantier, Anca Stoica, Rikke Lundorf, Carina Lynnerup Pedersen, Micael Loemstrup, Thomas Hartig Braunstein, Martin Fredensborg Rath (Faculty of Health and Medical Sciences, University of Copenhagen, Denmark), and Nina Rostgaard (Department of Neurosurgery, Rigshospitalet) for technical input and/or assistance. We thank Professor Thomas Jentsch (University of Hamburg, Germany) and Professor Jinwei Zhang (University of Dundee, UK) for providing us with the KCC1 and KCC4 antibodies and the team around Nikolaj Lillear (Department of Cardiothoracic Surgery, Rigshospitalet, Denmark) for access to blood/CSF from experimental pigs.

**Author contributions**

NM, EKO, ABS, DB, KT, TLTB, CRR designed the research; EKO, ABS, DB, NJG, KT, TLTB, SDL, SNA, TZ, SGH, AHS, FV executed experiments/analyzed data. PRK and VK established the mathematical model. NM, EKO, ABS drafted the manuscript. All authors participated in the finalization of the manuscript. All authors read and approved the final manuscript.
Funding
This work was funded by the Novo Nordisk Foundation; Tandem program (NNF17OC024718, to NV), Independent Research Fund Denmark (0134-00077B to NM), the Hartmann Foundation (to NV), the Lundbeck Foundation (R276-2018-403 to NM and R285-2018-3005 to TLTB), IMK Almene Fond (to NM), the Friis Foundation (to ABS), the DFC (FOR2795 - Ro23272/13-1 and 13-2, to CRR), the Absalon foundation (to SGH and AHS), Toyota-Fonden (to SGH and AHS), Fidelity Bermuda Foundation (to VK), and Swiss National Science Foundation (182685, to VK).

Data availability
We confirm that all data from this study will be available upon request. All scripts for the gene annotation and analysis can be found at https://github.com/SorenNorge/MacAulayLab-RNAseq1.

Declarations

Ethics approval and consent to participate
Animal experiments were in compliance with the Directive 2010/63/EU on the Protection of Animals used for Scientific Purposes. Use of human samples was approved by the Ethical Committees of the Capital Region of Denmark, approval number H-18046630.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen, Denmark. 2 Institute of Physiology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland. 3 Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen, Denmark. 4 Institute of Neurobiology, Heinrich Heine University Düsseldorf, Universitätsstrasse 1, 40225 Düsseldorf, Germany. 5 Danish Dementia Research Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Received: 2 March 2022   Accepted: 13 July 2022
Published online: 29 August 2022

References
1. Rubin RC, Henderson ES, Ommaya AK, Walker MD, Rall DP. The production of cerebrospinal fluid in man and its modification by acetazolamide. J Neurosurg. 1966;25:430–6.
2. Hladky SB, Barrand MA. Fluid and ion transfer across the blood-brain and blood-cerebrospinal fluid barriers; a comparative account of mechanisms and roles. Fluids Barriers CNS. 2016;13:19.
3. MacAulay N, Keep RF, Zeuthen T. Cerebrospinal fluid production by the choroid plexus: a century of barrier research revisited. Fluids Barriers CNS. 2022;19:26.
4. Bothwell SW, Janigro D, Patabendige A. Cerebrospinal fluid dynamics and intracranial pressure elevation in neurological diseases. Fluids Barriers CNS. 2019;16:9.
5. Jessen NA, Munk AS, Lundgaard I, Nedergaard M. The lymphatic system: a beginner’s guide. Neurochem Res. 2015;40:2583–99.
6. Ma Q, Ineichen BV, Detmar M, Proulx ST. Outflow of cerebrospinal fluid is predominantly through lymphatic vessels and is reduced in aged mice. Nat Commun. 2017;8:1434.
7. Proulx ST. Cerebrospinal fluid outflow: a review of the historical and contemporary evidence for arachnoid villi, perineural routes, and dural lymphatics. Cell Mol Life Sci. 2021;78:2429–57.
8. Mokri B. The Monaco-Kelle hypothesis: applications in CSF volume depletion. Neurology. 2001;56:1746–8.
9. Ziebell M, Wettelesv J, Tissel M, Gluud C, Juhiher M. Flow-regulated versus differential pressure-regulated shunt valves for adult patients with normal pressure hydrocephalus. Cochrane Database Syst Rev. 2013. https://doi.org/10.1002/14651858.CD009706.pub2.
10. Kolbø Månsson P, Johansson S, Ziebell M, Juhrler M. Forty years of shunt surgery at Rigshospitalet, Denmark: a retrospective study comparing past and present rates and causes of revision and infection. BMJ Open. 2017;7:e013389.
11. Piper RJ, Kalyvas AV, Young AM, Hughes MA, Jamjoom AA, Fouyas IP. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev. 2015;2015:CD003434.
12. Wall M, McDermott MP, Kieburtz KD, Corbett JF, Feldon SE, Friedman DI, Katz DM, Kellett JL, Schron EB, Kupersmith MJ. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014;311:1641–51.
13. Digre KB, Bruce BB, McDermott MP, Galetta KM, Balcer LJ, Wall M. Quality of life in idiopathic intracranial hypertension at diagnosis: iIH Treatment Trial results. Neurology. 2015;84:2449–56.
14. Damkier HH, Brown PD, Praetorius J. Cerebrospinal fluid secretion by the choroid plexus. Physiol Rev. 2013;93:1847–92.
15. Steffensen AB, Oernbo EK, Stoica A, Gerkau NJ, Barbuskaite D, Tritsaris K, Rose CR, MacAulay N. Cotransporter-mediated water transport underlying cerebrospinal fluid formation. Nat Commun. 2018;9:2167.
16. Karimy JK, Zhang J, Kurland DB, Theriault BC, Duran D, Stokum JA, Furey CG, Zhou X, Mansuri MS, Montjo J, Vera A, DiLuna ML, Delpere E, Alper SL, Guelz M, Gerzanih V, Medzhovit R, Simard JM, Kahle KT. Inflammation-dependent cerebrospinal fluid hypersecretion by the choroid plexus epithelium in posthemorrhagic hydrocephalus. Nat Med. 2017;23:997–1003.
17. Hamann S, Herrera-Perez JF, Zeuthen T, Alvarez-Leefmans FJ. Cerebrospinal fluid transport of water by the Na\(^+\)K\(^+\)-2Cl\(^-\) cotransporter NKCC1 in mammalian epithelial cells. J Physiol. 2010;588:4089–101.
18. Zeuthen T, MacAulay N. Cotransport of water by Na\(^+\)K\(^+\)-2Cl\(^-\) cotransporters expressed in Xenopus oocytes. NKCC1 versus NKCC2. J Physiol. 2012;590:1139–54.
19. Choe S, Rosenberg JM, Abramson J, Wright EM, Grabe M. Water permeation through the sodium-dependent galactose cotransporter vSGLT. Biophys J. 2010;99:6.6–8.
20. Steffensen AB, Zeuthen T. Cerebrospinal fluid transport in the choroid plexus epithelium: from amphibians to mammals. In: Praetorius J, Blazer-Yost B, Damkier HH, editors. Role of the choroid plexus in Health and Disease. New York: Springer; 2020. p. 99–124.
21. MacAulay N, Zeuthen T. Water transport between CNS compartments: contributions of aquaporins and cotransporters. Neuroscience. 2010;168:941–56.
22. Albert MS, DelKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Ganst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Cantillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.
23. Elkin N, Mamarou A, Klinge P, Bergsneider M, Black PM. Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery. 2005;57:54–16.
24. Kilcenny C, Browne W, Cuthill IC, Emerson M, Altman DG. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 2010;160:1577–9.
25. Karimy JK, Kahle KT, Kurland DB, Yu E, Gerzanchiz V, Simard JM. A novel method to study cerebrospinal fluid dynamics in rats. J Neurosci Methods. 2015;241:78–84.
26. Guild SJ, McBryde FD, Malpas SC. Recording of intracranial pressure in conscious rats via telemetry. J Appl Physiol. 1985;19(11):576–81.
27. del Campo M, Mollenhauer B, Bertolotio A, Engelbohrs S, Hampel H, Simonssen AH, Kapak K, Kruse N, Bastard NL, Lehmann S, Molinuevo JL, Parret-Leiander A, Sáez-Valero J, Saka E, Urbani S, Vanmechelen E, Verbeek M, Vissel PI, Teunissen C. Recommendations to standardize preanalytical confounding factors in Alzheimer’s and
Parkinson’s disease cerebrospinal fluid biomarkers: an update. Biomark Med. 2012;6:419–30.

29. Diamond JM, Bossert WH. Standing-gradient osmotic flow: A mechanism for coupling of water and solute transport in epithelia. J Gen Physiol. 1967;50:2061–83.

30. Stoseck C, Garaschuk O, Holthoff K, Konnerth A. In vivo two-photon calcium imaging of neuronal networks. Proc Natl Acad Sci USA. 2003;100:7319–24.

31. Lykke K, Toller K, Fett PW, Erker T, Macaulay N, Losscher W. The search for NKCC1–selective drugs for the treatment of epilepsy: structure–function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation–chloride cotransporter NKCC1A. Epilepsy Behav. 2016;59:92–9.

32. Stoica A, Larsen BR, Assentoff M, Holm R, Holt LM, Vilhardt F, Vilsøn B, Lykke-Hartmann K, Olsen ML, Macaulay N. The αβ2δ isoform combination dominates the astrocytic Na+/K+-ATPase activity and is rendered nonfunctional by the a2G301R familial hemiplegic migraine type 2-associated mutation. Glia. 2017;65:177–93.

33. Pedersen AK, Mendes Lopes de Melo J, Mørup N, Tritsaris K, Pedersen SF. Tumor microenvironment conditions alter Akt and Na+/H+ exchanger NHE1 expression in endothelial cells more than hypoxia. Implications for endothelial cell function in cancer. BMC Cancer. 2017;17:542.

34. Rose CR, Ransom BR. Intracellular sodium homeostasis in rat hippocampal astrocytes. J Physiol. 1996;491:291–305.

35. Keep RF, Xiang J, Betz AL. Potassium cotransport at the rat choroid plexus. Am J Physiol Regul Integr Comp Physiol. 2003;285:R1488–95.

36. Bouzouina EV, Praetorius T, Vírková LV, Nielsen S, Boron WF, Aalkjaer C. Na+-dependent HC03− uptake into the rat choroid plexus epithelium is partially DIDS sensitive. Am J Physiol Cell Physiol. 2005;289:C1448–56.

37. Keep RF, Xiang J, Betz AL. Potassium cotransport at the rat choroid plexus. Am J Physiol Regul Integr Comp Physiol. 2003;285:R1488–95.

38. Davis H, King WR. Densities of cerebrospinal fluid of human beings. Anesthesiology. 1954;15:666–70.

39. Arakaki X, McCleary P, Techy M, Chiang J, Luo L, Fonteh AN, Armstrong B, Levy D, Harrington MG. Na, K-ATPase alpha isoforms at the blood–cerebrospinal fluid-trigeminal nerve and blood-retina interfaces in the rat. Fluids Barriers CNS. 2013;10:14.

40. Bouzouina EV, Praetorius T, Vírková LV, Nielsen S, Boron WF, Aalkjaer C. Na+-dependent HC03− uptake into the rat choroid plexus epithelium is partially DIDS sensitive. Am J Physiol Cell Physiol. 2005;289:C1448–56.

41. Baasch Christensen L, Cheng L, Brewer JR, Bartsch U, Fenton RA, Damkier HH, Praetorius T. Multiple Na+,K+-ATPase subunits colocalize in the brush border of mouse choroid plexus epithelial cells. Int J Mol Sci. 2021;22:1569.

42. Boedtkjer E, Bunch L, Pedersen SF. Physiology, pharmacology and pathophysiology of the pH regulatory transport proteins NHE1 and NBCn1: similarities, differences, and implications for cancer therapy. Curr Pharm Des. 2012;18:1345–71.

43. Chen FF, Villafuerte FC, Swietach P, Cobden PM, Vaughan-Jones RD. S0859, an N-cyanoarylphosphamide inhibitor of sodium-bicarbonate cotransport in the heart. Br J Pharmacol. 2008;153:972–82.

44. Davson H, Segal MB. The effects of some inhibitors and accelerators of sodium transport on the turnover of 22Na in the cerebrospinal fluid and the brain. J Physiol. 1970;209:131–53.

45. Dent T, Boulton SF. Physiology, pharmacology and pathophysiology of the pH regulatory transport proteins NHE1 and NBCn1: similarities, differences, and implications for cancer therapy. Curr Pharm Des. 2012;18:1345–71.

46. Boedtkjer E, Bunch L, Pedersen SF. Physiology, pharmacology and pathophysiology of the pH regulatory transport proteins NHE1 and NBCn1: similarities, differences, and implications for cancer therapy. Curr Pharm Des. 2012;18:1345–71.

47. Damkier HH, Prasad V, Hubner CA, Praetorius T. NHE1 is a luminal Na+/H+ exchanger in mouse choroid plexus and is targeted to the basolateral membrane in Ncbe/Nbcn2-null mice. Am J Physiol Cell Physiol. 2009;296:C1291–C1300.

48. Larsen BR, Stoica A, Macaulay N. Managing brain extracellular K(+) during neuronal activity: the physiological role of the Na+-K+-atpase subunit α3 isoform. Front Physiol. 2016;7:141.

49. Davson H, Segal MB. The effects of some inhibitors and accelerators of sodium transport on the turnover of 22Na in the cerebrospinal fluid and the brain. J Physiol. 1970;209:131–53.

50. Untert V, Kovermann P, Gerkau NJ, Gensch T, Rose CR, Fahlke C. Glutamate transporter-associated anion channels adjust intracellular chloride concentrations during glial maturation. Glia. 2017;65:388–400.

51. Thomas RA. Experimental displacement of intracellular pH and the mechanism of its subsequent recovery. J Physiol. 1984;354:113–22.

52. Boedtkjer E, Bunch L, Pedersen SF. Physiology, pharmacology and pathophysiology of the pH regulatory transport proteins NHE1 and NBCn1: similarities, differences, and implications for cancer therapy. Curr Pharm Des. 2012;18:1345–71.

53. Christensen HL, Barbuskaite D, Rojek A, Malte H, Christensen IB, Lykke-Hartmann K, Olsen ML, MacAulay N. The α2β2 isoform combination dominates the astrocytic Na+/K+-ATPase activity and is rendered nonfunctional by the a2G301R familial hemiplegic migraine type 2-associated mutation. Glia. 2017;65:177–93.

54. Christensen HL, Barbuskaite D, Rojek A, Malte H, Christensen IB, Lykke-Hartmann K, Olsen ML, MacAulay N. The α2β2 isoform combination dominates the astrocytic Na+/K+-ATPase activity and is rendered nonfunctional by the a2G301R familial hemiplegic migraine type 2-associated mutation. Glia. 2017;65:177–93.

55. Christensen HL, Barbuskaite D, Rojek A, Malte H, Christensen IB, Lykke-Hartmann K, Olsen ML, MacAulay N. The α2β2 isoform combination dominates the astrocytic Na+/K+-ATPase activity and is rendered nonfunctional by the a2G301R familial hemiplegic migraine type 2-associated mutation. Glia. 2017;65:177–93.

56. Bouzouina EV, Praetorius T, Vírková LV, Nielsen S, Boron WF, Aalkjaer C. Na+-dependent HC03− uptake into the rat choroid plexus epithelium is partially DIDS sensitive. Am J Physiol Cell Physiol. 2005;289:C1448–56.

57. Baasch Christensen L, Cheng L, Brewer JR, Bartsch U, Fenton RA, Damkier HH, Praetorius T. Multiple Na+,K+-ATPase subunits colocalize in the brush border of mouse choroid plexus epithelial cells. Int J Mol Sci. 2021;22:1569.

58. Christensen HL, Barbuskaite D, Rojek A, Malte H, Christensen IB, Lykke-Hartmann K, Olsen ML, MacAulay N. The α2β2 isoform combination dominates the astrocytic Na+/K+-ATPase activity and is rendered nonfunctional by the a2G301R familial hemiplegic migraine type 2-associated mutation. Glia. 2017;65:177–93.

59. Christensen HL, Barbuskaite D, Rojek A, Malte H, Christensen IB, Lykke-Hartmann K, Olsen ML, MacAulay N. The α2β2 isoform combination dominates the astrocytic Na+/K+-ATPase activity and is rendered nonfunctional by the a2G301R familial hemiplegic migraine type 2-associated mutation. Glia. 2017;65:177–93.

60. Bouzouina EV, Praetorius T, Vírková LV, Nielsen S, Boron WF, Aalkjaer C. Na+-dependent HC03− uptake into the rat choroid plexus epithelium is partially DIDS sensitive. Am J Physiol Cell Physiol. 2005;289:C1448–56.

61. Bouzouina EV, Praetorius T, Vírková LV, Nielsen S, Boron WF, Aalkjaer C. Na+-dependent HC03− uptake into the rat choroid plexus epithelium is partially DIDS sensitive. Am J Physiol Cell Physiol. 2005;289:C1448–56.

62. Bouzouina EV, Praetorius T, Vírková LV, Nielsen S, Boron WF, Aalkjaer C. Na+-dependent HC03− uptake into the rat choroid plexus epithelium is partially DIDS sensitive. Am J Physiol Cell Physiol. 2005;289:C1448–56.
